Is lipid profile determination necessary in women wishing to use oral contraceptives?

Abstract Introduction Although coronary heart disease in users of combined oral contraceptives (COCs) is rare, one of the principal risk factors for its occurrence is dyslipidemia. Objective To evaluate the prevalence of dyslipidemia in women wishing to use COCs, and its association with known clini...

Full description

Saved in:
Bibliographic Details
Published in:Contraception (Stoneham) 2013-06, Vol.87 (6), p.801-805
Main Authors: Machado, Rogério Bonassi, Bernardes, Carine Rejane, de Souza, Isadora Matias, Santana, Narayana, Morimoto, Mariana
Format: Article
Language:English
Subjects:
Adolescent
Adult
Biological and medical sciences
Body Mass Index
Brazil - epidemiology
Cardiovascular risk
Combined oral contraceptive
Contraceptives, Oral - adverse effects
Cross-Sectional Studies
Disorders of blood lipids. Hyperlipoproteinemia
Drug Monitoring
Dyslipidemia
Dyslipidemias - blood
Dyslipidemias - chemically induced
Dyslipidemias - epidemiology
Dyslipidemias - etiology
Female
Genital system. Reproduction
Gynecology. Andrology. Obstetrics
Hospitals, University
Humans
Hypercholesterolemia
Lipid profile
Lipids - blood
Medical sciences
Metabolic diseases
Obesity - physiopathology
Obstetrics and Gynecology
Outpatient Clinics, Hospital
Overweight - physiopathology
Pharmacology. Drug treatments
Prevalence
Risk Factors
ROC Curve
Smoking - adverse effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Although coronary heart disease in users of combined oral contraceptives (COCs) is rare, one of the principal risk factors for its occurrence is dyslipidemia. Objective To evaluate the prevalence of dyslipidemia in women wishing to use COCs, and its association with known clinical risk factors in order to evaluate the need to determine the lipid profile in this population. Study Design Cross-sectional study involving 516 women aged 18–40 years, 54% nulligravid, who wished to use COCs and presented no contraindications. Dyslipidemia was classified according to the National Cholesterol Educational Project Adult Treatment Panel III guidelines, which define levels of total cholesterol ≥ 200 mg/dL, high-density lipoprotein cholesterol < 40 mg/dL, triglycerides > 150 mg/dL, and low-density lipoprotein cholesterol ≥ 160 mg/dL as an abnormal lipid profile. The lipid profile was determined, and the association between clinical risk factors and the presence of dyslipidemia was evaluated by the chi-squared test and logistic regression. The receiver operating characteristic curve was constructed to compare body mass index (BMI) and smoking relevance for dyslipidemia. Results The prevalence of dyslipidemia was 33.9%. Smoking and BMI were significantly associated with the presence of dyslipidemia, with sensitivity of 31.3–54% and specificity of 41.9–67.7% for diagnosis of dyslipidemia, respectively. Conclusion The high prevalence of dyslipidemia could justify lipid profile evaluation before prescribing a COC. BMI and smoking represent modest predictive markers for the presence of dyslipidemia in candidates for the use of combined oral contraceptives.
ISSN:0010-7824
1879-0518
DOI:10.1016/j.contraception.2012.12.003